Suite 200
Philadelphia, PA 19107
(215) 955-1234
(215) 955-1390 fax
Most Recent Peer-reviewed Publications
- Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis
- Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases
- Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10+ IFN-γ+-producing CD4+ T cells
- Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis
- TCR stimulation upregulates MS4a4B expression through induction of AP-1 transcription factor during T cell activation
Medical School
Shiraz University
Residency
Hospital of University of Pennsylvania (HUP)
Fellowship
Hospital of University of Pennsylvania (HUP)
Board Certification
Neurology
Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Research and Clinical Interests
My research focuses on...
Multiple Sclerosis is an autoimmune disease of the central nervous system that affects over 400,000 Americans and over 2 million worldwide. My research focuses on the pathogenesis of multiple sclerosis using the animal model of this disease, experimental autoimmune encephalomyelitis (EAE). At the present, we are focusing on three main areas:
1) The role of IL-12/IL-17/IL-23 axis in the pathogenesis of EAE and multiple sclerosis.
Specifically, studies will examine IL-12/IL-17/IL-23 produced by antigen presenting cells (APC) from the periphery (macrophages and dendritic cells) and from the central nervous system (CNS) microglia in EAE. In addition to a better understanding of the pathogenesis of inflammatory demyelination, the information derived from this study will be helpful if these cytokines are to be considered as targets for therapy in MS.
2) The effect of the Bowman-Birk protease inhibitor on the course of EAE. This study has the potential to provide a novel, safe, and effective therapy for multiple sclerosis.
3) Mechanisms of intravenous tolerance in EAE.
This study will elucidate the mechanisms by which intravenous myelin antigens induce tolerance and suppress clinical disease in EAE. This study will provide a novel method for analyzing the migration and functional status of infiltrating cells in the CNS, in particular, and in target organs of other autoimmune diseases. It has the potential as a possible therapy for autoimmune diseases."